Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of GSK2189242A in Children
NCT00985751Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2009
- Primary completion
- Oct 2010
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised trial of GSK 2189242A in pneumococcal disease (5 arms), sponsored by GSK. Primary endpoint: Number of Subjects With Fever > 40.0°C (Rectal Temperature). Started Nov 2009; status: completed.
02
Drugs
GSK 2189242A
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT00985751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00985751.